The first large trial of a promising Alzheimer’s drug provides convincing evidence that it slows the impact of the devastating disease.



Memantine is the first Alzheimer’s drug designed to tackle the late stages of the neurodegenerative illness and works on a different system in the brain to other existing drugs.



Barry Reisberg, a psychiatrist at the New York School of Medicine, and colleagues saw marked improvements during the six months for which patients were given memantine.



“The drug seems to be slowing the progressive loss of basic capacities [like bathing and dressing] by at least half,” says Reisberg.
More here.

0